EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer

Inclusion Criteria:

• Known or suspected non-small cell lung cancer; patients without histologically orcytologically documented non-small cell lung cancer (NSCLC) must be estimated by theirphysician to have at least 75% probability of having NSCLC; the probability ofmalignancy will be predicted on the basis of known probabilities of individualclinical characteristics using a Bayesian model

• Clinical or pathologic stage I to III; patients in whom pre-surgical staging has notdefinitively establish stage IV disease are eligible

• Tumor mass at least 1.5 cm in maximum diameter must be present on computed tomography (CT) scan and must be included in the planned surgical biopsy or resection

• Patient must be planning to undergo a surgical staging or treatment procedure (including mediastinoscopy, wedge resection, lobectomy, or pneumonectomy) and have theclinical and physiological status appropriate for this procedure

• Performance status 0-2

• Bilirubin within normal limits

• Creatinine within normal limits or, if elevated, a creatinine clearance of at least 60mL/min/m^2 (EF5 is primarily excreted via the kidney)

• White blood cell (WBC) > 2000/mm^3

• Platelets > 100,000/mm^3

Exclusion Criteria:

• Pregnancy or breast feeding; a negative serum pregnancy test is required of any womanof childbearing potential prior to enrollment; pregnant women are excluded from thisstudy; breastfeeding should be discontinued if the mother is treated with EF5

• Allergy to IV contrast dye

• History of grade III or IV peripheral neuropathy as defined by the National CancerInstitute (NCI) Common Terminology Criteria (CTC)